In preclinical pancreatic cancer models, CDK4/6 inhibitors can influence tumor growth (Chou et al., 2018) and combine to sustain antitumor effects following chemotherapy (Salvador-Barbero et al., 2020). This evidence concerns the gene CDK4 and neoplasm.